<DOC>
	<DOC>NCT00647933</DOC>
	<brief_summary>The objectives of this study were to study the pharmacokinetics, pharmacodynamics and safety of Org 36286 after a single subcutaneous administration in healthy females.</brief_summary>
	<brief_title>An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Mestranol</mesh_term>
	<mesh_term>Noracycline</mesh_term>
	<mesh_term>Lynestrenol</mesh_term>
	<criteria>Good physical and mental health; Body Mass Index between 18 and 29 kg/m^2; Good venous accessibility; Clinically relevant abnormal blood chemistry, hematology and/or urinalysis at screening; Hypertension (sitting diastolic blood pressure &gt; 90 mmHg and/or systolic blood pressure &gt; 150 mmHg); Contraindications for the use of oral contraceptives or gonadotropins; PAPsmear (= III) according to the Papanicolaou classification; History of endocrine abnormalities such as hyperprolactinaemia, polycystic ovary syndrome or any evidence of ovarian dysfunction; Primary ovarian failure; Ovarian cysts or enlarged ovaries, not related to polycystic ovarian disease; Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound investigation; Ovarian surgery; Smoking more than 10 cigarettes or equivalents a day; History (within 12 months) of alcohol or drugs abuse; Blood donation (&gt; 200 ml) within 90 days prior to screening; Administration of investigational drugs within 90 days prior to start Org 36286.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Females</keyword>
	<keyword>Corifollitropin alfa</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>